YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma

International Journal of Cancer

Volumn 129, Issue 5, 2011, Pages 1265-1276

  Holzmüller, Regina ^a   Mantwill, Klaus ^a   Haczek, Cornelia ^a   Rognoni, Emanuel ^a   Anton, Martina ^a   Kasajima, Atsuko ^b   Weichert, Wilko ^b   Treue, Denise ^b   Lage, Hermann ^b   Schuster, Tibor ^a   Schlegel, Jürgen ^a   Gänsbacher, Bernd ^a   Holm, Per S ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c XVir Therapeutics GmbH   (Germany)

Author keywords

glioma; oncolytic adenovirus; temozolomide; virotherapy; YB 1

Indexed keywords

CISPLATIN; DAUNORUBICIN; E1A PROTEIN; ONCOLYTIC ADENOVIRUS; TEMOZOLOMIDE; VASCULOTROPIN; Y BOX BINDING PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER CELL CULTURE; CANCER REGRESSION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; SOUTHERN BLOTTING; VIRUS RECOMBINANT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, SOUTHERN; BLOTTING, WESTERN; BRAIN NEOPLASMS; CISPLATIN; COMBINED MODALITY THERAPY; DACARBAZINE; DAUNORUBICIN; GENE THERAPY; GENETIC VECTORS; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; VIRUS REPLICATION; Y-BOX-BINDING PROTEIN 1;

EID: 79959715402     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25783     Document Type: Article

References (48)

1. Wu J, Stratford AL, Astanehe A, Dunn SE,. YB-1 is a transcription/ translation factor that orchestrates the oncogenome by hardwiring signal transduction to gene expression. Transl Oncogenomics 2007; 2: 49-65.
2. Lasham A, Moloney S, Hale T, Homer C, Zhang YF, Murison JG, Braithwaite AW, Watson J,. The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J Biol Chem 2003; 278: 35516-23. (Pubitemid 37102323)
3. Wu J, Lee C, Yokom D, Cheang MC, Yorida E, Turbin D, Berquin IM, Mertens PR, Iftner T, Gilks CB, Dunn SE,. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res 2006; 66: 4872-9.
4. Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, Yasumoto K, Sugimachi K, Kuwano M,. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 2001; 7: 3151-5. (Pubitemid 32963838)
5. Bargou RC, Jürchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dörken B, Royer HD,. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997; 3: 378-80.
6. Stickeler E, Fraser SD, Honig A, Chen AL, Berget SM, Cooper TA,. The RNA binding protein YB-1 binds A/C-rich exon enhancers and stimulates splicing of the CD44 alternative exon v4. EMBO J 2001; 20: 3821-30. (Pubitemid 32691793)
7. Jurchott K, Bergmann S, Stein U, Walther W, Janz M, Manni I, Piaggio G, Fietze E, Dietel M, Royer HD,. YB-1 as a cell cycle-regulated transcription factor facilitating cyclin A and cyclin B1 gene expression. J Biol Chem 2003; 278: 27988-96. (Pubitemid 36899994)
8. Gaudreault I, Guay D, Lebel M,. YB-1 promotes strand separation in vitro of duplex DNA containing either mispaired bases or cisplatin modifications, exhibits endonucleolytic activities and binds several DNA repair proteins. Nucleic Acids Res 2004; 32: 316-327. (Pubitemid 38228631)
9. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ, Sorensen PH,. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009; 15: 357-9.
10. Soop T, Nashchekin D, Zhao J, Sun X, Alzhanova-Ericsson AT, Björkroth B, Ovchinnikov L, Daneholt B,. A p50-like Y-box protein with a putative translational role becomes associated with pre-mRNA concomitant with transcription. J Cell Sci 2003; 116: 1493-503. (Pubitemid 36527496)
11. Stratford AL, Habibi G, Astanehe A, Jiang H, Hu K, Park E, Shadeo A, Buys TP, Lam W, Pugh T, Marra M, Nielsen TO, et al., Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res 2007; 9: R61.
12. Mertens PR, Harendza S, Pollock AS, Lovett DH,. Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1. J Biol Chem 1997; 272: 22905-12. (Pubitemid 27386113)
13. Finkbeiner MR, Astanehe A, To K, Fotovati A, Davies AH, Zhao Y, Jiang H, Stratford AL, Shadeo A, Boccaccio C, Comoglio P, Mertens PR, et al., Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene 2009; 28: 1421-31.
14. Reardon DA, Wen PY,. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. The Oncologist 2006; 11: 152-64. (Pubitemid 43261762)
15. Stupp R, van den Bent MJ, Hegi ME,. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neuro Neurosci Rep 2005; 5: 198-206. (Pubitemid 40873035)
16. Desjardins A, Rich JN, Quinn JA, Vredenburgh J, Gururangan S, Sathornsumetee S, Reardon DA, Friedman AH, Bigner DD, Friedman HS,. Chemotherapy and novel therapeutic approaches in malignant glioma. Front Biosci 2005; 10: 2645-68. (Pubitemid 40905267)
17. Immonen A, Vapalahti M, Tyynelä K, Hurskainen H, Sandmair A, Vanninen R, Langford G, Murray N, Ylä-Herttuala S,. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 2004; 10: 967-72. (Pubitemid 39419922)
18. Tate MC, Aghi MK,. Biology of angiogenesis and invasion in glioma. Neurotherapeutics 2009; 6: 447-57.
19. Okada H, Kohanbash G, Zhu X, Kastenhuber ER, Hoji A, Ueda R, Fujita M,. Immunotherapeutic approaches for glioma. Crit Rev Immunol 2009; 29: 1-42.
20. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T,. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008; 71: 1372-80.
21. Sonabend AM, Ulasov IV, Lesniak MS,. Conditionally replicative adenoviral vectors for malignant glioma. Rev Med Virol 2006; 16: 99-115.
22. Holm PS, Lage H, Bergmann S, Jürchott K, Glockzin G, Bernshausen A, Mantwill K, Ladhoff A, Wichert A, Mymryk JS, Ritter T, Dietel M, et al., Multidrugresistant cancer cells facilitate E1-independent adenoviral replication: impact for cancer gene therapy. Cancer Res 2004; 64: 322-8. (Pubitemid 38114114)
23. Holm PS, Bergmann S, Jürchott K, Lage H, Brand K, Ladhoff A, Mantwill K, Curiel DT, Dobbelstein M, Dietel M, Gansbacher B, Royer HD,. YB-1 relocates to the nucleus in adenovirus-infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter. J Biol Chem 2002; 277: 10427-34. (Pubitemid 34968163)
24. Rognoni E, Widmaier M, Haczek C, Mantwill K, Holzmüller R, Gansbacher B, Kolk A, Schuster T, Schmid RM, Saur D, Kaszubiak A, Lage H, et al. Adenovirus-based virotherapy enabled by cellular YB-1 expression in vitro and in vivo. Cancer Gene Ther 2009; 16: 753-63.
25. Sauthoff H, Heitner S, Rom WN, Hay JG,. Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector. Hum Gene Ther 2000; 11: 379-88. (Pubitemid 30101948)
26. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, Belousova N, Curiel DT,. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-13. (Pubitemid 28520834)
27. Bieler A, Mantwill K, Holzmüller R, Jürchott K, Kaszubiak A, Stärk S, Glockzin G, Lage H, Grosu AL, Gansbacher B, Holm PS,. Impact of radiation therapy on the oncolytic adenovirus dl520: implications on the treatment of glioblastoma. Radiother Oncol 2008; 86: 419-27. (Pubitemid 351343876)
28. Yam PY, Li S, Wu J, Hu J, Zaia JA, Yee JK,. Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol Ther 2002; 5: 479-84. (Pubitemid 34308674)
29. Naldini L, Blömer U, Gage FH, Trono D, Verma IM,. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 1996; 93: 11382-8. (Pubitemid 26347130)
30. Bett AJ, Haddara W, Prevec L, Graham FL,. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A 1994; 91: 8802-6.
31. Nevins JR,. Mechanism of activation of early viral transcription by the adenovirus E1A gene product. Cell 1981; 26: 213-20. (Pubitemid 12244499)
32. Schilling D, Gehrmann M, Steinem C, De Maio A, Pockley AG, Abend M, Molls M, Multhoff G,. Binding of heat shock protein 70 to extracellular phosphatidylserine promotes killing of normoxic and hypoxic tumor cells. FASEB J 2009; 23: 2467-2477.
33. Del Valle L, Azizi SA, Krynska B, Enam S, Croul SE, Khalili K,. Reactivation of human neurotropic JC virus expressing oncogenic protein in a recurrent glioblastoma multiforme. Ann Neurol 2000; 48: 932-6.
34. Gluz O, Mengele K, Schmitt M, Kates R, Diallo-Danebrock R, Neff F, Royer HD, Eckstein N, Mohrmann S, Ting E, Kiechle M, Poremba C, et al., Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. J Clin Oncol 2009; 27: 6144-51.
35. Aghi M, Rabkins S, Martuza RL,. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 2006; 98: 38-50. (Pubitemid 43057091)
36. Chu RL, Post DE, Khuri FR, Van Meir EG,. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004; 10: 5299-312. (Pubitemid 39100464)
37. Hirose Y, Berger MS, Pieper RO,. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001; 61: 1957-63. (Pubitemid 32692013)
38. Ulasov IV, Sonabend AM, Nandi S, Khramtsov A, Han Y, Lesniak MS,. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. Br J Cancer 2009; 100: 1154-64.
39. Quirin C, Mainka A, Hesse A, Nettelbeck DM,. Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells. Int J Cancer 2007; 121: 2801-7. (Pubitemid 350136430)
40. 6-methylguanine-DNA methyltransferase promoter. Cancer Res 2007; 67: 11499-504.
41. 6-methylguanine-DNA methyltransferase. Mol Cancer Ther 2009; 8: 3276-84.
42. Mantwill K, Koehler-Vargas N, Bernshausen A, Bieler A, Lage H, Kaszubiak A, Surowiak P, Dravits T, Treiber U, Hartung R, Gansbacher B, Holm PS,. Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents. Cancer Res 2006; 66: 7195-202. (Pubitemid 44197698)
43. Grothey A, Galanis E,. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009; 6: 507-18.
44. Saito Y, Sunamura M, Motoi F, Abe H, Egawa S, Duda DG, Hoshida T, Fukuyama S, Hamada H, Matsuno S,. Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region. Cancer Gene Ther 2006; 13: 242-52. (Pubitemid 43255761)
45. Chamberlain MC, Johnston SK,. Salvage therapy with single agent bevacizumab for recurrent glioblastoma. J Neurooncol 2009; 96: 259-69.
46. Jensen RL,. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol 2009; 92: 317-35.
47. Li L, Lin X, Shoemaker AR, Albert DH, Fesik SW, Shen Y,. Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. Clin Cancer Res 2006; 12: 4747-54. (Pubitemid 44297829)
48. Shen BH, Hermiston TW,. Effect of hypoxia on Ad5 infection, transgene expression and replication. Gene Ther 2005; 12: 902-10. (Pubitemid 40852208)